Maris Hartmanis declines re-election for 2020

Corporate Information

English

IR

MAR

mfn-ci-other

News

Regulatory

Xbrane Biopharma AB (publ) ("Xbrane" or “the Company”) has today been informed by the Nomination Committee that Maris Hartmanis has declined re-election at the Annual General Meeting (AGM) 2020. The Nomination Committee will propose a replacing board member and this will be published in connection with the notice to the AGM.

Anders Tullgren, Xbrane’s Chairman of the Board, comments: “I would like to take this opportunity to thank Maris for his work on the Board since 2015. His involvement and expertise have been crucial in Xbrane’s journey from being a private company to the listing at Nasdaq Stockholm.”